DSIP: what the human research actually shows
A real sleep peptide with real human data that mostly predates the modern GLP-1 era. The opioid-withdrawal story is the strongest signal. The insomnia story is the most oversold.
Why I looked into this
DSIP is one of the few peptides I see discussed in both serious pharmacology circles and biohacker sleep forums, and the tone of those two conversations could not be more different. In the literature it is a cautious, modest story about a weak opiate-receptor effect and a signal in opioid withdrawal. On the forums it is framed as a fix-your-sleep-forever compound if you can just find a clean source.
Those two framings cannot both be right. I wanted to see which one the human evidence actually supports.
What DSIP actually is
DSIP is a nine-amino-acid peptide first isolated in 1977 by the Schoenenberger-Monnier group in Switzerland from the cerebral venous blood of rabbits that had been electrically stimulated into a slow-wave sleep state. The sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The synthetic form used in most human research is frequently called Emideltide.
The mechanism has never been fully pinned down. Proposed actions include weak agonism at opiate receptors, modulation of cortisol and growth-hormone release, and effects on hypothalamic sleep-regulating neurons. None of these mechanisms has the kind of clean, replicated receptor-binding story that a modern regulatory submission would require.
What the human research shows
Do published human trials exist?
Yes. Published human studies exist on PubMed. They are old.
The bulk of the human record is from the 1980s and 1990s. Two distinct clinical questions were asked: does DSIP improve chronic insomnia, and does DSIP blunt the somatic symptoms of alcohol and opioid withdrawal? Both questions got small, mostly single-investigator answers. No large modern trial exists. No US regulatory Phase 2 or Phase 3 record exists.
What evidence actually exists?
The main human studies are:
- Dick P et al., European Neurology, 1984. Open-label study of approximately 100 inpatients in acute alcohol or opiate withdrawal given intravenous DSIP. The authors reported that clinical withdrawal symptoms disappeared or improved markedly in 97 percent of alcohol-dependent and 87 percent of opiate-dependent patients, with headache as the most common adverse event.
- Morelli S et al., Journal of Substance Abuse Treatment, 1998. Open clinical trial of DSIP for opioid detoxification (PMID 9617990). Similar pattern of rapid somatic symptom reduction.
- Schneider-Helmert D and Schoenenberger GA, European Neurology, 1983 and 1984. Small double-blind placebo-controlled trials in chronic insomniac patients. Polysomnography showed improved sleep efficiency and reduced sleep latency with DSIP versus placebo.
- Schneider-Helmert D, Neuropsychobiology, 1992 (PMID 1299794). Sixteen chronic insomniac patients, double-blind, seven nights of DSIP vs placebo. Objective sleep improved. The authors concluded, and this is the key line most writeups leave out, that short-term DSIP treatment of chronic insomnia is not likely to be of major therapeutic benefit.
What the research does not show
The research does NOT show:
- A modern Phase 2 or Phase 3 trial from the last decade.
- Any US regulatory safety package. The trials were European and were not submitted to FDA for any indication.
- Long-term safety data past a few weeks of administration.
- That DSIP is reliably superior to standard-of-care benzodiazepines for insomnia, or to buprenorphine or methadone for opioid withdrawal. Direct head-to-head comparisons do not exist.
- Any independent replication of the Dick 1984 withdrawal findings by an unrelated group outside Europe.
Known safety signals in humans
Published human safety signals are remarkably benign on paper: transient headache, mild nausea, and occasional dizziness at the time of infusion. Several reviews characterize DSIP as one of the better-tolerated neuropeptides tested in humans, with no serious adverse events reported in the trials above.
What the published record does not contain: any long-term safety surveillance, any effect on drug interactions, any pregnancy safety data, any study in adolescents, and any accounting of adverse events in the current research-use-only market.
FDA and legal status in the US
The July 24, 2026 Pharmacy Compounding Advisory Committee meeting will consider DSIP (and Emideltide, the named synthetic form) for possible inclusion on the 503A bulk drug substances list. The three indications under consideration are opioid withdrawal, chronic insomnia, and narcolepsy, alongside Epitalon for insomnia on the same day.
PCAC inclusion is not FDA approval. Even a positive vote begins a multi-step rulemaking process that historically takes more than a year. As of today, compounding access in the US is not authorized, and the status quo holds until the formal rulemaking completes.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for DSIP specifically
The specific source-safety wrinkle with DSIP is that the market is dominated by research-use-only vials of a peptide that has never been commercially manufactured to pharmaceutical standards in the US. Peptide identity and purity testing for DSIP is not a standard analytical method the way it is for insulin. Two vials labeled identically from two suppliers can contain different purity profiles, different degradation products, and, at the bad end, different peptides entirely.
The DSIP discussion has also been confused for years by the close similarity between DSIP itself and other neuropeptides like Selank. A casual shopper can easily end up with a product that is not what the label says.
Cost reality
Research-use-only vials sell in the $40 to $120 range. A legitimate 503A compounding pharmacy, if one compounds DSIP after the July review, would charge considerably more because of the oversight and the physician pathway attached.
Cheaper is not safer. A bargain-priced vial is a signal that the supplier cut somewhere, and identity testing is the first thing cut.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license?
- Do you provide a certificate of analysis from an independent third-party laboratory, not in-house testing?
- Do you require a valid prescription from a licensed clinician?
- Do you have a physical US address and a phone number I can call?
- What specific identity test did you use to confirm this vial contains DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and not a structurally similar neuropeptide?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used DSIP. If I were evaluating it for a specific clinical question, the only one I would take seriously based on the published record is opioid withdrawal symptom management in a supervised inpatient setting. For insomnia, I would not. The Schneider-Helmert group, which produced most of the positive data, eventually published their own walk-back that short-term DSIP is unlikely to be of major therapeutic benefit. That is a conclusion from the friendliest possible source.
The forum discourse about DSIP as a perfect sleep peptide has essentially no basis in the primary literature. The strongest insomnia result is a double-blind trial of sixteen middle-aged patients where sleep efficiency improved for the duration of the trial and then regressed. That is a real finding. It is not a foundation for daily use in healthy adults with mild sleep complaints.
The opioid withdrawal data is more interesting to me, and it is also forty years old, which is a problem. Nothing about the modern opioid epidemic resembles the 1984 European inpatient population. Buprenorphine and methadone-based protocols were not standardized when the Dick 1984 study ran. The relevant question today is whether DSIP adds anything to a modern protocol, and there is no study that answers that.
For someone curious about DSIP, I would read the Dick 1984 paper and one of the Schneider-Helmert insomnia reviews directly. For someone considering it for sleep, I would use the primary evidence to set expectations at ‘modest short-term effect at best, then regression’ instead of the marketing framing. For someone considering it for withdrawal, this is not a self-administered peptide. It is inpatient-setting material or it is nothing.
Questions to ask your doctor
If you are considering DSIP, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have read the Dick 1984 European trial and the Schneider-Helmert insomnia studies on DSIP. Do you know this literature, and do you think a 40-year-old European inpatient data set generalizes to current US practice?
- If I were interested in DSIP specifically for sleep, what standard-of-care options would you want me to have tried or ruled out first?
- If DSIP is discussed at all for opioid withdrawal, is this something that would be monitored in a supervised setting, or is it not a realistic outpatient option?
- Do you know of a licensed 503A compounding pharmacy we could work with together under a supervised protocol?
- What signs or symptoms should I report immediately if I were ever on a sleep-acting neuropeptide and something did not feel right?
- Is there anything in my history, medications, or current labs that would make a weak opiate-receptor-active peptide a poor idea for me specifically?
What to do next
Read the 1980s trials directly
Dick 1984 in European Neurology is the reference paper on withdrawal. Schneider-Helmert 1992 is the more honest read on insomnia. Both are free on PubMed abstract.
Open the primer →Bring the packet, set expectations
Bring the visit-prep packet. Go in expecting a modest short-term effect on sleep, not a cure, and ask whether modern options have been ruled out first.
Get the packet →Ask about identity, not just purity
The main source-safety risk for DSIP is getting a different peptide in the vial than what the label says. Insist on sequence-level identity testing.
Open the checklist →Sources
- Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. “Successful treatment of withdrawal symptoms with delta sleep-inducing peptide.” European Neurology. 1984;23(5):364-371. PMID 6328354.
- Dick P, Grandjean ME, Tissot R. “DSIP in the treatment of withdrawal syndromes from alcohol and opiates.” European Neurology. 1984. PMID 6548969.
- Morelli S, Scolari B, Ravasi F, et al. “Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial.” Journal of Substance Abuse Treatment. 1998. PMID 9617990.
- Schneider-Helmert D. “DSIP in insomnia.” European Neurology. 1984;23(5):358-363. PMID 6391925.
- Schneider-Helmert D, Schoenenberger GA. “A clinical trial with DSIP.” European Neurology. 1984. PMID 6391926.
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. “Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.” Neuropsychobiology. 1992. PMID 1299794.
- FDA Federal Register. “Pharmacy Compounding Advisory Committee, Notice of Meeting.” Docket FDA-2025-N-6895, April 16, 2026. Federal Register notice.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Epitalon
Under PCAC review the same day as DSIP, also for insomnia. Russian-origin anti-aging peptide with the same single-investigator problem.
Semax
Russian-origin peptide also under PCAC review July 24. Same genre of evidence problem: real trials, narrow investigator base, no Western replication.
BPC-157
The flagship No-Human-Trials peptide in the July review. Useful contrast to DSIP, which at least has 1980s data.